LifeMD, Inc. (LFMDP) Stock Price & Analysis
LifeMD, Inc. (LFMDP) — MoonshotScore 22/100 (Weak band), calculated Nov 18, 2026. Price $18.75 (-2.55%), as of the Nov 19, 2026 trading session; market cap $133M.
Educational signal · not a buy or sell recommendation · How to read this
LifeMD, Inc. · LFMDP
LifeMD, Inc. operates as a direct-to-patient telehealth platform, connecting individuals with healthcare professionals across the United States for various medical needs, including specialized care in men's health, dermatology, and primary care. The company leverages a portfolio of distinct telehealth brands and a SaaS platform, distributing services directly to consumers and through partner networks.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · LifeMD (LFMDP)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fragile balance sheet and stalling growth. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Fragile; Valuation: Fair; Growth Durability: Fading; Momentum: Quiet.
- quarterly revenue $47M (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 4 of the last 8 reports
- Altman Z -2.37 · Piotroski F 2
Holding back: balance-sheet strain, soft growth
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 21 | Weak | |
| 23 | Weak | |
| 22 | Weak | |
| 22 | Weak | |
| 22 | Weak | |
| 22 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $18.75 | |
| Change on the day | -2.55% | |
| Market capitalisation | $133M | |
| Shares traded on the day | 642 |
Price & events
Other perspectives
Council score for LifeMD (LFMDP): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is LifeMD (LFMDP), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. LifeMD, Inc. (LFMDP) is the company analyzed here. It employs 347 people. In Q2 FY2026 it reported revenue of $47M and net income of -$7M. The market values it at $133M.
What do the latest results show for LifeMD (LFMDP)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $47M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $47M | -$7M | -$0.16 (diluted) |
| Q1 FY2026 | $50M | -$9M | -$0.20 (diluted) |
| Q4 FY2025 | $47M | -$1M | -$0.05 (diluted) |
| Q3 FY2025 | $60M | -$4M | -$0.10 (diluted) |
What are the financial strengths and risks for LifeMD (LFMDP)?
Short answer · as of
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is balance-sheet strain, soft growth. The distress and quality screens read Altman Z -2.37 · Piotroski F 2. Trailing ratios: ROA -33.1% · current ratio 0.80 · earnings yield -20.7% · free-cash-flow yield -15.1%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -2.37 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How is LifeMD scored?
Short answer · as of
A same-model peer rank is unavailable in the current peer set. The MoonshotScore combines business quality, financial safety, valuation, growth durability and momentum; open “Why this rating?” for the method and drivers.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 11, 2026
- Transactions
- 6
- Identified insiders
- 6
- Purchases
- 0
- Sales
- 0
- Other transactions
- 6
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held LFMDP in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported LFMDP in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about LifeMD (LFMDP)?
What Investors Ask About LifeMD (LFMDP)
These answers are editorial: 1 of these 9 answers is drawn from the LFMDP research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for LFMDP?
LFMDP carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is LFMDP a good stock to buy?
Stock Expert AI does not rate LFMDP buy, sell or hold. LifeMD, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the LFMDP stock price today?
The last price recorded for LifeMD, Inc. (LFMDP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does LifeMD, Inc. do?
LifeMD, Inc. operates as a direct-to-patient telehealth enterprise, connecting individuals across the United States with licensed healthcare professionals for a broad spectrum of medical needs.
What are the key factors to evaluate for LFMDP?
LifeMD, Inc. (LFMDP) holds a MoonshotScore in the low range. This model fosters patient loyalty and provides a stable foundation for long-term growth in the evolving healthcare landscape. Not financial advice.
How frequently does LFMDP data refresh on this page?
LFMDP's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven LFMDP's recent stock price performance?
LifeMD, Inc. (LFMDP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified portfolio of specialized telehealth brands (ShapiroMD, RexMD, LifeMD Primary Care, Cleared, Nava MD). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LFMDP overvalued or undervalued right now?
LifeMD, Inc. (LFMDP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research LFMDP before investing?
Before investing in LifeMD, Inc. (LFMDP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 10 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com